Ariad: Court denies motion to dismiss Amgen patent lawsuit

By Lisa Kerner

Charlotte, N.C., Sept. 12 - The U.S. District Court for the District of Delaware denied Ariad Pharmaceuticals, Inc.'s motion to dismiss the lawsuit filed by Amgen, Inc. and affiliated entities relating to two products, Enbrel and Kineret.

Amgen is seeking a declaratory judgment that these products do not infringe U.S. Patent No. 6,410,516 covering methods of treating human disease by regulating NF-(kappa)B cell-signaling activity and that this patent is invalid.

Ariad is a pharmaceutical company based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.